Unlock your next-level market advantage
Improve your commercial success, operational efficiency, and competitive edge by leveraging the industry’s most comprehensive and adaptable clinical trial technology platform.
The Partnership to Win, Innovate, and Outperform
Over 240 CRO Partners, including 9 of the top 10, trust Medidata for its technology, expertise, AI-driven insights, and the world’s largest patient-level clinical trial data from 9+ million outcomes across 30,000+ trials.
Niche CROs to leading players – across phases and therapy areas – maximize value by identifying revenue gaps, responding to sponsors’ needs and budgets, and optimizing clinical development.
Collaborate with a specialized team committed to driving your success, innovation, and performance.
Why CROs Choose and Trust Medidata
Innovators, disruptors, and industry leaders, our CRO Partners rely on our proven technology and unmatched partnership experience to navigate complexities and adapt to varying trial sizes, thereby gaining a competitive advantage and outperforming in any trial environment.
CRO Partners
including 9 out of the top 10 CROs, 134 for 5+ and 212 for 10+ years
Clinical Trials
including 2,000+ rare disease studies and 90% of oncology approvals in 2022
Patients
achieving >95% of patient compliance when using our tools
of FDA-approved Drugs
developed on Medidata software in 2022
Success Stories from CROs
Innovating Together
“Our partnership with Medidata allows us to continue to bring our customers the level of patient focus and insights they need and expect. Making the Medidata Platform available to our clients was an important step to enabling us to accelerate clinical trial development for our customers – small and mid-sized biotech companies.”
Solving Trial Complexity
“The technology from Medidata drives our success in bringing new clinical studies to Latin America by automating our workflow and streamlining manual processes. This is a tremendous opportunity to make our region a showcase for clinical research and the development of therapies to benefit patients.”
A 15-year Partnership Win
“Our partnership definitely shifts the dynamics in terms of benefits along the cost, time, and value continuum.”
A Decade of Partnership
“PROMETRIKA’s accreditation in RTSM allows us to offer greater efficiencies in clinical trial management to all of our Sponsor partners.”
Leverage our Partner Program
Win. Innovate. Outperform.
Access exclusive tools and resources to drive growth and deliver on your sponsors’ needs for faster, more efficient, high-quality clinical trials.
Differentiate your business with the industry’s most comprehensive clinical trial technology across all phases, all therapeutic areas and levels of complexity. Leverage a world-class set of dedicated experts helping you to win more and outperform your competition.
Our Current Partners
Whether our CRO Partners aim to fast-track study initiation, optimize trial outsourcing, enhance monitoring intelligence, or elevate the operational efficiency of their clinical trials, they trust Medidata to guide them every step of the way.
Become a Partner
Gain advantage with a leading Partner Program. Leverage a global program dedicated to helping CROs of all sizes discover and secure opportunities for commercial success.
Win, outperform, and innovate in a fiercely competitive market.
Resources for CROs
Data is the Future of Clinical Trials
Improve their study integrity, reduce risks, optimize patient safety, and increase their trial success rates. How do CROs lead with data?
The Ultimate DCT Guide: CRO Edition
Build your leadership in the future of Decentralized Clinical Trials with insights and resources tailored for CROs.
The CRO Partner Playbook
With a powerful strategic technology partnership, dive into a blueprint to win, innovate, and outperform with standout trial results.
Win. Innovate. Outperform.
Propel your commercial success, operational efficiency, and competitive edge.
Unlock your next-level market advantage with the technology, expertise, and support dedicated to you and your sponsors.